Vision Research Center Eye Associates of New Mexico | Albuquerque, NM

Research site

(Unclaimed)

Location

4411 The 25 Way Suite 325, Albuquerque, New Mexico, United States of America

Site insights

Top conditions

Top treatments

KHK4951

GT005

OPL-0401

ANX007

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 9 total trials

4D-150 in Patients With Diabetic Macular Edema

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Enrolling

Diabetic Macular Edema

Diabetic Retinopathy

Biological: Aflibercept IVT

Biological: 4D-150 IVT

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling

Geographic Atrophy

Drug: ANX007

Other: Sham Administration

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting

Non-proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

Drug: Placebo

Drug: OPL-0401 Dose 1

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Enrolling

Diabetic Retinopathy (DR)

Genetic: RGX-314 Dose 1

Genetic: RGX-314 Dose 2